GAO and nutritionals
This article was originally published in The Tan Sheet
Executive Summary
Report examining existing federal mechanisms for ensuring the safety of supplements and functional foods and the accuracy of their labeling/advertising claims is slated for July release. The analysis, a self-initiated project by the General Accounting Office, was spurred by consumer interest and growth in the industry. The analysis will incorporate data from approximately two dozen entities, including FDA, NIH, FTC, the California Department of Health, trade groups, nutrition and consumer groups, academia and six food companies. GAO's August 1999 report questioning FDA's reliance on AER data to support a proposed rule restricting the use of ephedrine alkaloids in supplements was a key factor in the agency's recent withdrawal of the proposed reg's dosing and duration of use limits (1"The Tan Sheet" March 6, p. 9)
You may also be interested in...
Ephedrine Alkaloids Dosing, Duration Limits Withdrawn Pending Public Input
FDA will consider "public comment of the widest kind" from the "layperson to health professionals to scientists" in analyzing and changing portions of the June 1997 proposed rule on ephedrine alkaloids in dietary supplements, Commissioner Jane Henney, MD, testified at a congressional hearing Feb. 29.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands